12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Crizotinib regulatory update

Pfizer began submission of a rolling NDA to FDA for crizotinib to treat patients with advanced non-small cell...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >